TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03482661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: magnetic steering
Description: The capsule was controlled to pass through the pylorus by magnet steering.
Study: NCT02631187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bielefeld balloon
Description: Balloon Eustachian tuboplasty = dilatation of the cartilaginous Eustachian tube with a balloon catheter device performed with endoscopic control under general anaesthetic
Study: NCT02146846

Intervention type: DRUG
Intervention: Imatinib
Description: Patients with chronic myeloid leukemia who receive Imatinib as treatment
Study: NCT02111369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: After a discussion of the risks and benefits of propranolol therapy, the patient will then be given a prescription by the principal investigator for propranolol. This prescription will consist of a starting dose of generic immediate-release at 10 mg three times daily (30 mg each day) with an increase in dose in 5-7 days if there is no effect (60 mg each day) and if the patient had demonstrated no side effects. Dose may be increased to 240 mg each day depending on patient improvement and side effect profile.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin
Description: At the second evaluation, patient will receive botulinum toxin injections. The risks and benefits of botulinum toxin therapy will be explained to the patient, and bilateral injections will take place.
Study: NCT03431948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg given by intravenous infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg given by intravenous infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabiralizumab
Description: Cabiralizumab 4 mg/kg given by intravenous infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urelumab
Description: Urelumab 8 mg given by intravenous infusion every 4 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Radiation to metastatic lesion(s) given at assigned dose levels based on lesion location and dose level being tested at time of enrollment. Doses range from 30 - 50 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Radiation to metastatic lesion(s) given at assigned dose levels based on lesion location and dose level being tested at time of enrollment. Doses range from 30 - 50 Gy.
Study: NCT04697563

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: real laser beam administered

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebolaser
Description: no laser beam admitted
Study: NCT02404506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesilate
Description: Eribulin mesiylate 1.1mg/m2 d1, 8 every 3 weeks until Progressive disease PD
Study: NCT02739139

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AlphaBrain
Description: Alpha BRAIN® (Onnit Labs LLC) is a multi-ingredient nutritional supplement that purports to enhance cognitive function in healthy adults. The commercially available product contains 12 naturally occurring compounds

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: AlphaBrain
Description: Alpha BRAIN® (Onnit Labs LLC) is a multi-ingredient nutritional supplement that purports to enhance cognitive function in healthy adults. The commercially available product contains 12 naturally occurring compounds
Study: NCT01813487

Intervention type: DRUG
Group type: OTHER
Intervention: HBsAg vaccine with Entecavir
Study: NCT01750918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Each capsule contains 50 mg or 75 mg of GSK2118436; 50 mg strength capsules are Swedish orange (dark red) opaque hypromellose size 2 capsules and 75 mg strength capsules are pink opaque hypromellose size 1 capsules. The initial dosing regimen will be twice daily (BID) continuous oral daily dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Each capsule contains 50 mg or 75 mg of GSK2118436; 50 mg strength capsules are Swedish orange (dark red) opaque hypromellose size 2 capsules and 75 mg strength capsules are pink opaque hypromellose size 1 capsules. The initial dosing regimen will be twice daily (BID) continuous oral daily dosing.
Study: NCT03505320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin will be administered as a 2-hour IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin will be administered as a 2-hour IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Leucovorin will be administered as a 2-hour IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Leucovorin will be administered as a 2-hour IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Leucovorin will be administered as a 2-hour IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Fluorouracil will be administered as IV bolus over 5 to 15 minutes and continuous IV infusion over 46 to 48 hours or per institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Fluorouracil will be administered as IV bolus over 5 to 15 minutes and continuous IV infusion over 46 to 48 hours or per institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Fluorouracil will be administered as IV bolus over 5 to 15 minutes and continuous IV infusion over 46 to 48 hours or per institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid
Description: Folnic acid will be administered as a 2-hour IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid
Description: Folnic acid will be administered as a 2-hour IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid
Description: Folnic acid will be administered as a 2-hour IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Nivolumab will be administered intravenously according to institutional standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered as a 1-hour IV infusion.
Study: NCT03272698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: IV Ketamine 0.50 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: IV Ketamine 0.50 mg/kg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ECT
Description: ECT with unilateral or bilateral electrode placement and monitoring of seizure threshold by the half-age method
Study: NCT00709592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study: NCT01450280

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 CS
Description: ChAd63 CS 5x10\^9 vp intra-muscularly Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 CS, MVA CS
Description: ChAd63 CS 5x10\^9 vp intra-muscularly Day 0; MVA CS 2x10\^8 pfu intra-muscularly Day 56

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 CS
Description: ChAd63 CS 5x10\^10 vp intra-muscularly Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63, MVA CS
Description: ChAd63 CS 5x10\^10 vp intra-muscularly Day 0; MVA CS 2x10\^8 pfu intra-muscularly Day 56
Study: NCT00079443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03037905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SignatureSuite OR Integration System by STERIS Corporation
Description: SignatureSuite OR Integration System by STERIS Corporation is a device that controls audio and visual components of the operating room environment in order to provide a more relaxing and calming operating room environment for patients prior to surgery and on emergence from anesthesia after surgery.
Study: NCT01666132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intramyocardial injection of BM cells
Description: only intramyocardial, NOGA guided injection on BM cells.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intramyocardial / intracoronary injection of BM cells
Description: combination of intramyocardial, NOGA guided injection of BM cells and intracoronary injection of those cells

Intervention type: OTHER
Group type: OTHER
Intervention: Best medical therapy
Description: initially no intervention; crossover to therapy 6 months after enrollment
Study: NCT02894073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: skin transilluminator
Description: VeinViewer
Study: NCT03381040

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Lyft
Description: Restylane® Lyft is a sterile gel of hyaluronic acid with lidocaine generated by Streptococcus species of bacteria, chemically cross-linked with BDDE (the cross linker), stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL. Lyft is intended to be used for facial tissue augmentation. It is recommended that the product be used for shaping the contours of the face and the correction of folds using the co-packed needles. Given the very high lift capacity of Lyft, it is often used when the skin envelope is normal or thicker than normal, as the contours of the product may be palpable in the presence of thin skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Volyme
Description: Restylane® Volyme is a sterile, biodegradable, viscoelastic, non-pyrogenic, clear, colorless, and homogeneous soft hyaluronic acid gel with a high lifting capacity. Volyme is intended for injection into the supraperiostic zone or subcutis to augment the volume of the cheeks.~Given Volyme's viscoelastic and lifting capacities, it is best used when there is significant loss of volume and a thin skin envelope.
Study: NCT03615105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HPC(A) stem cell allograft
Description: All patients will receive anti-thymocyte globulin based conditioning followed by a G-CSF mobilized, peripheral blood hematopoietic progenitor cell HPC(A) product depleted of TCR-α/β+ Tlymphocytes using the CliniMACS system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 200 mg IV flat dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 200 mg IV flat dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 200 mg IV flat dose

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin
Description: Rabbit antithymocyte globulin dosing per nomogram. This dynamic nomogram is based on absolute lymphocyte count at the start of conditioning and can result in either 2 or 3 day ATG administration. If a patient requires 2 day administration the subjequent chemotherapies may be moved forward by one day at the treating physician's discretion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin
Description: Rabbit antithymocyte globulin dosing per nomogram. This dynamic nomogram is based on absolute lymphocyte count at the start of conditioning and can result in either 2 or 3 day ATG administration. If a patient requires 2 day administration the subjequent chemotherapies may be moved forward by one day at the treating physician's discretion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin
Description: Rabbit antithymocyte globulin dosing per nomogram. This dynamic nomogram is based on absolute lymphocyte count at the start of conditioning and can result in either 2 or 3 day ATG administration. If a patient requires 2 day administration the subjequent chemotherapies may be moved forward by one day at the treating physician's discretion.
Study: NCT03517085

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DTX401
Description: DTX401 administered as a single peripheral intravenous (IV) infusion

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DTX401
Description: DTX401 administered as a single peripheral intravenous (IV) infusion

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DTX401
Description: DTX401 administered as a single peripheral intravenous (IV) infusion

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DTX401
Description: DTX401 administered as a single peripheral intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroid regimen
Description: prednisone or prednisolone to manage alanine aminotransferase (ALT) elevation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroid regimen
Description: prednisone or prednisolone to manage alanine aminotransferase (ALT) elevation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroid regimen
Description: prednisone or prednisolone to manage alanine aminotransferase (ALT) elevation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroid regimen
Description: prednisone or prednisolone to manage alanine aminotransferase (ALT) elevation
Study: NCT03429959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOCKNLEG
Description: Donning and doffing success compared with the two study stockings, wearing the assigned study stocking for a day, Patient Quesationnaire on donning and doffing success and wearing comfort of each study stocking

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SIGVARIS Cotton
Description: SIGVARIS Cotton
Study: NCT01242774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Oral administration of panobinostat given 3 times a week (administered on weeks 2 and 3 of a 4 week cycle) in combination with induction chemotherapy (idarubicin and cytarabine.
Study: NCT03950336

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Prebiotics
Description: Oligofructose-enriched inulin \[a combination of shorter chain oligofructose, Degree of Polymerisation (DP) 3 - 9 and longer chain inulin (DP ≥ 10), in a 50:50 ratio ± 10 %\] 12 g/day for 6 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Low n-6 PUFA Diet
Description: The Mediterranean diet pattern (MDP) with increased n-3 PUFA, saturated fatty acids (SFA) and monounsaturated fatty acids (MUFA) and reduced n-6 PUFAs food intake will be adopted as suitable Low n-6 PUFA diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Maltodextrin
Description: Maltodextrin consists of D-glucose units connected in chains of variable length (DP 3-17). The glucose units are primarily linked with α(1→4) glycosidic bonds. Maltodextrin is easily hydrolyzed by the intestinal enzymes and thus does not have an effect on colonic microbiota. Maltodextrin (5 g/days for 6 weeks) will be used as a placebo for the prebiotic treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Control Diet
Description: Participants who will not be assigned to Low n-6 PUFA diet will be advised to follow the Canada's Food Guide recommendations (Control diet). As Canada's Food Guide Diet is also designed with the aim to support healthy eating and prevention of metabolic and chronic disorders, this diet may not be considered as a true comparator for the Low n-6 PUFA diet intervention.
Study: NCT03460418

Intervention type: OTHER
Intervention: Phone contact
Description: Assessment of the different outcomes by means of a phone contact

Intervention type: OTHER
Intervention: Phone contact
Description: Assessment of the different outcomes by means of a phone contact
Study: NCT01160666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab will be administered at 10 mg/kg at Days 0, 14, 28 and then every 28 days until week 24 for all patients and week 48 for those considered responders at week 28.
Study: NCT04205266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: IV iron infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: oral iron therapy
Study: NCT04868903

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Half the subjects will be randomized to the low dose vitamin D therapy (400 IU/day), which will serve as the control group, and half to moderate (4,000 IU/day) or high (10,000 IU/day). Study participants will have the option between being randomized to the low versus moderate or the low versus high dose arms.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Half the subjects will be randomized to the low dose vitamin D therapy (400 IU/day), which will serve as the control group, and half to moderate (4,000 IU/day) or high (10,000 IU/day). Study participants will have the option between being randomized to the low versus moderate or the low versus high dose arms.
Study: NCT00033345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo pill taken daily during run-in period
Study: NCT04545697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medcorder
Description: Medcorder is a smartphone app that is HIPAA compliant for the use of on patient recordings of consults with healthcare providers.
Study: NCT04585360

Intervention type: OTHER
Intervention: Questionnaires evaluating anxiety and depression symptoms, tiredness, and quality of life
Description: Realization of specific questionnaires evaluating:~* psychiatric symptoms (self-assessment according to the SLC-90R questionnaire and hetero-assessment by the internist doctor of the center according to the M.I.N.I. questionnaire)~* fatigue (Multidimensional Fatigue Inventory (MFI-20), French version, in self-assessment)~* quality of life (SF36 self-assessment questionnaire)
Study: NCT01794416

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopic epicardial ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endocardial catheter ablation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable loop recorder

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable loop recorder
Study: NCT03460418

Intervention type: OTHER
Intervention: Phone contact
Description: Assessment of the different outcomes by means of a phone contact
Study: NCT00694161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fx-1006A
Description: Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for 12 months
Study: NCT01731015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Grade Oxygen
Description: At the study visits, MRI 'studies' will be performed using the same MR scanner (a 3.0-Tesla (T) TRIO MRI system (Siemens Medical Systems)). Lung morphology and function will be acquired using conventional 1H MRI followed by 1H MRI with oxygen as a gaseous contrast agent. For both series the subject will lie down in a supine position on the magnet bed with a standard 1H Torso coil for imaging. Subjects are scanned on room air and then the subjects are switched from room air to 100% oxygen and exhaled O2/CO2 are monitored (Oxigraf Capnograph) until steady state is achieved (in our experience \~ 1-2 minutes). The 100% oxygen MRI imaging is commenced (the average exposure time is usually 5-6 minutes with a maximum exposure of 15 minutes) after which the subjects are switched to room air. After steady state is achieved a second room air scan is completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Grade Oxygen
Description: At the study visits, MRI 'studies' will be performed using the same MR scanner (a 3.0-Tesla (T) TRIO MRI system (Siemens Medical Systems)). Lung morphology and function will be acquired using conventional 1H MRI followed by 1H MRI with oxygen as a gaseous contrast agent. For both series the subject will lie down in a supine position on the magnet bed with a standard 1H Torso coil for imaging. Subjects are scanned on room air and then the subjects are switched from room air to 100% oxygen and exhaled O2/CO2 are monitored (Oxigraf Capnograph) until steady state is achieved (in our experience \~ 1-2 minutes). The 100% oxygen MRI imaging is commenced (the average exposure time is usually 5-6 minutes with a maximum exposure of 15 minutes) after which the subjects are switched to room air. After steady state is achieved a second room air scan is completed.
Study: NCT01591590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDG PET-CT
Description: All patients will undergo FDG PET-CT at inclusion and 2 weeks after

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diffusion MRI
Description: All patients will undergo Diffusion MRI at inclusion and 2 weeks later

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples (plasma preparation and CTC)
Study: NCT03767569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myo-inositol
Description: Myo-inositol and Folic acid daily

Intervention type: DRUG
Group type: OTHER
Intervention: Folic Acid
Description: Folic Acid daily
Study: NCT03508011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297
Description: The dose levels will be escalated following a modified 3+3 dose escalation scheme.
Study: NCT01684774

Intervention type: DRUG
Intervention: Bupivacaine

Intervention type: DRUG
Intervention: Bupivacaine
Study: NCT03274089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kiosk intervention group
Description: SEEK automates the management of patients with stable well-controlled chronic disease. SEEK has the following capabilities:~* Collects patient information using patient-specific identification~* Prompts the user for answers to screening questions for acute conditions~* Measures relevant physiological parameters: blood pressure, height, weight; and calculates body mass index~* Triages patients based on responses to screening questions, physiological parameters and blood test results~* Provides recommendations to the patient on the care plan, self management and lifestyle choices